Loading...
XNAS
CERT
Market cap1.90bUSD
May 20, Last price  
11.69USD
1D
-0.76%
1Q
-16.68%
IPO
-65.20%
Name

Certara Inc

Chart & Performance

D1W1MN
XNAS:CERT chart
P/E
—
P/S
4.92
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.39%
Rev. gr., 5y
13.06%
Revenues
385m
+8.70%
163,719,000208,511,000243,530,000286,104,000335,644,000354,337,000385,148,000
Net income
-12m
L-78.23%
-33,258,000-8,926,000-49,397,000-13,266,00014,731,000-55,357,000-12,051,000
CFO
80m
-2.77%
11,592,00038,025,00044,810,00060,388,00092,543,00082,755,00080,466,000
Earnings
Aug 04, 2025

Profile

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
URL
https://www.certara.com/
IPO date
Dec 11, 2020
Employees
1,150
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
385,148
8.70%
354,337
5.57%
335,644
17.32%
Cost of revenue
333,286
302,602
259,963
Unusual Expense (Income)
NOPBT
51,862
51,735
75,681
NOPBT Margin
13.47%
14.60%
22.55%
Operating Taxes
(5,133)
214
4,024
Tax Rate
0.41%
5.32%
NOPAT
56,995
51,521
71,657
Net income
(12,051)
-78.23%
(55,357)
-475.79%
14,731
-211.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,402)
(2,962)
BB yield
0.23%
0.12%
Debt
Debt current
8,306
7,395
7,988
Long-term debt
38,804
302,127
315,222
Deferred revenue
1,049
1,070
2,815
Other long-term liabilities
306,558
39,209
22,121
Net debt
(132,073)
73,420
82,888
Cash flow
Cash from operating activities
80,466
82,755
92,543
CAPEX
(1,625)
(1,777)
(12,529)
Cash from investing activities
(112,368)
(79,550)
(27,837)
Cash from financing activities
(21,010)
(9,447)
(7,363)
FCF
53,261
66,570
59,903
Balance
Cash
179,183
234,951
236,586
Long term investments
1,151
3,736
Excess cash
159,926
218,385
223,540
Stockholders' equity
(140,085)
(122,220)
(67,507)
Invested Capital
1,536,986
1,511,906
1,477,990
ROIC
3.74%
3.45%
4.94%
ROCE
3.61%
3.59%
5.13%
EV
Common stock shares outstanding
160,393
158,936
159,354
Price
10.65
-39.45%
17.59
9.46%
16.07
-43.46%
Market cap
1,708,183
-38.90%
2,795,689
9.17%
2,560,825
-39.87%
EV
1,576,110
2,869,109
2,643,713
EBITDA
119,895
107,806
128,151
EV/EBITDA
13.15
26.61
20.63
Interest
21,520
22,916
17,773
Interest/NOPBT
41.49%
44.29%
23.48%